HyperQure™ RDN System
― Precise, Safe & Complete.
HyperQure™ is the world’s first laparoscopic, extravascular renal denervation system. By ablating from outside the artery, it delivers precision, safety, and lasting therapeutic benefit.
This approach enables complete, 360° circumferential ablation, ensuring consistent performance across diverse anatomies
— for predictable, durable outcomes.
Initially created for resistant hypertension, HyperQure™ expands the boundaries in the treatment of cardiovascular disease, by unlocking deeper pathways.
Hypertension
― Silent, Deadly & Everywhere.
Hypertension is the leading cause of death worldwide, a silent epidemic affecting 1.9 billion adults. It drives the global burden of cardiovascular disease and increases the risk of heart attack, stroke, kidney failure, and dementia.
While medications and lifestyle changes help many, they are not a cure, just lifelong management. And for nearly 10% of patients, even this approach fails to deliver results.
Each year, hypertension claims over 10 million lives. The urgency is clear
― We need better, more lasting solutions to meet the needs of those left behind.
Advancing the Science of
Renal Denervation
Renal denervation (RDN) is a therapeutic procedure that lowers blood pressure by disrupting overactive renal sympathetic nerves. While promising, conventional intravascular techniques often fail to reach deeper or variably located nerves, leading to inconsistent results.
HyperQure™ introduces a new standard with the world’s first laparoscopic, extravascular RDN system. By ablating from outside the artery, it enables complete, circumferential denervation — offering greater precision, consistency, and clinical potential in treating resistant hypertension.
Latest
29 Oct 2024
DeepQure Presents Clinical Results of Laparoscopic RDN at TCT 2024, Demonstrating Cutting-edge Technology and Innovation
From Hypertension to Beyond
DeepQure was founded to transform how we treat hypertension — not just by managing the condition, but by addressing its root causes through targeted nerve ablation.
But hypertension is only the beginning. Backed by a robust intellectual property portfolio spanning more than 10 countries, our platform opens new frontiers in cardiovascular care — from atrial fibrillation to other autonomic conditions.
At DeepQure, we’re not just building devices; we’re building a new standard for interventional therapy.
DeepQure Insights
Hypertension, RDN, and Beyond
Discover how our team is advancing the science of renal denervation and shaping the future of cardiovascular care
